{
    "title": "Medical Product Communications Act of 2017",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medical Product Communications Act \nof 2017''.\n\nSEC. 2. COMMUNICATIONS REGARDING INTENDED USES OF DRUGS AND DEVICES; \n              SCIENTIFIC EXCHANGE.\n\n    The Federal Food, Drug, and Cosmetic Act is amended by inserting \nafter section 201 of such Act (21 U.S.C. 321) the following:\n\n``SEC. 201A. INTENDED USES OF DRUGS AND DEVICES.\n\n    ``(a) Intended Use.--For purposes of this Act, including sections \n301(d), 502(f)(1), 505, 510, and 515 and for purposes of section 351 of \nthe Public Health Service Act, the intended use of a drug, biological \nproduct, or device--\n            ``(1) shall be determined by reference to the objective \n        intent of the manufacturer and sponsor of such drug, biological \n        product, or device, or persons acting on the manufacturer's or \n        sponsor's behalf, as demonstrated by statements contained in \n        labeling, advertising, or analogous oral statements; and\n            ``(2) shall not be determined by reference to--\n                    ``(A) actual or constructive knowledge of the \n                manufacturer or sponsor that such drug, biological \n                product, or device will be used in a manner that varies \n                from the use approved for marketing under section 505, \n                510, or 515 of this Act or section 351 of the Public \n                Health Service Act; or\n                    ``(B) scientific exchange as described in \n                subsection (b).\n    ``(b) Scientific Exchange.--\n            ``(1) In general.--For purposes of this Act, including \n        sections 301(d), 502(f)(1), 505, 510(k), and 515 and for \n        purposes of section 351 of the Public Health Service Act, the \n        scientific exchange of information about a drug, biological \n        product, or device, as described in paragraph (2), shall not \n        constitute labeling, advertising, or evidence of a new intended \n        use.\n            ``(2) Requirements for scientific exchange.--A \n        communication by a manufacturer or sponsor, or a person acting \n        on behalf of a manufacturer or sponsor, about the \n        manufacturer's or sponsor's drug, biological product, or \n        device, or use of such drug, biological product, or device, \n        that has not been approved for marketing under section 505, \n        510, or 515 of this Act or section 351 of the Public Health \n        Service Act, about a device or use of such device that has not \n        been approved or cleared for marketing under section 510 or 515 \n        of this Act, or about information that is not included in the \n        drug, biological product, or device labeling, constitutes \n        scientific exchange when--\n                    ``(A) the communication is supported by \n                scientifically appropriate and statistically sound \n                data, studies, or analyses;\n                    ``(B) the communication includes a conspicuous and \n                prominent statement that the drug, biological product, \n                or device, or use of such drug, biological product, or \n                device, that is the subject of the communication, has \n                not been approved for marketing under section 505, 510, \n                or 515 of this Act or section 351 of the Public Health \n                Service Act, or that such communication includes \n                information that is not contained in the drug, \n                biological product, or device labeling, as applicable; \n                and\n                    ``(C) for communications relating to a drug, \n                biological product, or device that has not been \n                approved for marketing under section 505, 510, or 515 \n                of this Act or section 351 of the Public Health Service \n                Act, or relating to a use of a drug, biological \n                product, or device that has not been so approved, the \n                manufacturer and sponsor make no claims that such \n                product or use has been demonstrated to be safe or \n                effective.\n            ``(3) Scientific exchange described.--The scientific \n        exchange of information under paragraph (2) may include--\n                    ``(A) dissemination of scientific findings in \n                scientific or lay media;\n                    ``(B) publication of results of scientific studies;\n                    ``(C) letters to the editor in defense of public \n                challenges;\n                    ``(D) communications at scientific or medical \n                conferences or meetings;\n                    ``(E) dissemination of medical or scientific \n                publications, reference texts, or clinical practice \n                guidelines;\n                    ``(F) communication, both proactive and reactive, \n                of information regarding a manufacturer's research and \n                development efforts;\n                    ``(G) communication, both proactive and reactive, \n                of scientific, medical, or technical information or \n                findings, including communication of such information \n                by personnel in scientific, medical, or clinical \n                development departments of manufacturers; and\n                    ``(H) communication, both proactive and reactive, \n                of health care economic and health outcomes \n                information, including communication of such \n                information delivered by or on behalf of the health \n                care economic or health outcomes departments of \n                manufacturers to an individual, group of individuals, \n                or entity responsible for contributing toward, \n                advising, or facilitating decisionmaking related to \n                health care resource or utilization management, \n                including decisions about the selection of drugs, \n                biological products, or devices for a population of \n                patients.\n            ``(4) Rule of construction.--Nothing in this subsection \n        shall be construed--\n                    ``(A) to authorize the Secretary to require that a \n                manufacturer or sponsor submit an application, \n                certification, or other such submission, or to seek the \n                Secretary's review or approval, before, during, or \n                subsequent to engaging in scientific exchange; or\n                    ``(B) to limit the ability of manufacturers or \n                sponsors to engage in communications or activities that \n                properly constitute scientific exchange as that term is \n                described in paragraph (2) but that are not specified \n                in paragraph (3).''."
}